Some immunological parameters and interleukin level associated with Chronic myelogenous leukemia patients in Al Anbar governorate
DOI:
https://doi.org/10.52783/jns.v14.1776Keywords:
cytokines, disease duration, Chronic myeloid leukemia, INF ⍺, TNF-⍺.Abstract
Context: Tumor necrosis factor (TNF)-α and other cytokines play a role in the pathophysiology of chronic myeloid leukemia (CML), however their prognostic importance in these conditions remains unclear. The authors evaluated the correlation between serum cytokine levels and clinical outcomes in individuals with CML in the present study.
Methodology: Serum concentrations of TNF-a, interleukin (IL)-1 receptor antagonist, IL-6, IL-5, IL-3, IFN 1a, C3, and C5 were assessed in patients with CML1 or CML2 seeking treatment at Al-Anbar Oncology Center. Univariate and multivariate analyses were conducted to examine relationships with clinical outcomes.
Outcomes: Elevated TNF-a levels were associated with diminished performance status, increased leukocyte counts, and heightened cytokine levels. Additionally, a robust positive association was observed between TNF-a, INF-a, IL-1a, IL-6, IL-5, IL-3, C3, and C5 in patients with chronic myeloid leukemia (CML).
Conclusions: Elevated serum levels of TNF-a, INF-a, IL-1a, IL-6, IL-5, IL-3, C3, and C5 in CML patients signify the severity of the disease.
Downloads
Metrics
References
Sulaeman, K. M. (2018). Cytogenetic study of acute myelogenous leukemia in Erbil City-Iraqi Kurdistan region. Tikrit Journal of Pure Science, 23(1), 1-8.
2. Zbaar, S. A. (2017). Serum level of TNF-alpha in patients with chronic myeloid leukemia on Imatinib therapy. Tikr Med J, 22, 54-60.
Yokota, A., Hirai, H., Sato, R., Adachi, H., Sato, F., Hayashi, Y., ... & Maekawa, T. (2019). C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells. Blood advances, 3(3), 476-488.
Puzzolo, M. C., Breccia, M., Mariglia, P., Colafigli, G., Pepe, S., Scalzulli, E., ... & Foà, R. (2022). Immunomodulatory effects of IFNα on T and NK cells in chronic myeloid leukemia patients in deep molecular response preparing for treatment discontinuation. Journal of Clinical Medicine, 11(19), 5594.
Yokota, A., Hirai, H., Sato, A., Kamio, N., Hayashi, Y., Miura, Y., ... & Maekawa, T. (2017). IFN-α Upregulates the Expression of C/EBPβ and Induces Myeloid Differentiation and Exhaustion of CD34+ CML Stem Cells. Blood, 130, 2863.
Ujvari, D., Malyukova, A., Zovko, A., Yektaei-Karin, E., Madapura, H. S., Keszei, M., ... & Salamon, D. (2022). IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors. Oncoimmunology, 11(1), 2109861.
Omsland, M., Andresen, V., Gullaksen, S. E., Ayuda-Durán, P., Popa, M., Hovland, R., ... & Gjertsen, B. T. (2020). INTERFERON ALPHA AND TYROSINE KINASE INHIBITORS INCREASE TUNNELING NANOTUBES (TNT) FORMATION AND CELL ADHESION IN CHRONIC MYELIOD LEUKEMIA (CML) CELL LINES. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 34(3), 3773.
Kanlı, Z., Cabadak, H., & Aydın, B. (2023). Potential antiproliferative and apoptotic effects of pilocarpine combined with TNF alpha in chronic myeloid leukemia cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 396(7), 1513-1524.
9. Shen, N., Liu, S., Cui, J., Li, Q., You, Y., Zhong, Z., ... & Zhu, X. (2019). Tumor necrosis factor α knockout impaired tumorigenesis in chronic myeloid leukemia cells partly by metabolism modification and miRNA regulation. OncoTargets and therapy, 2355-2364.
De Boer, B., Sheveleva, S., Apelt, K., Vellenga, E., Mulder, A. B., Huls, G., & Schuringa, J. J. (2021). The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis. Haematologica, 106(12), 3067.
Bulaeva, E., Pellacani, D., Nakamichi, N., Hammond, C. A., Beer, P. A., Lorzadeh, A., ... & Eaves, C. J. (2020). MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus. Blood, The Journal of the American Society of Hematology, 136(24), 2764-2773.
Sharma, K., Singh, U., Rai, M., Shukla, J., Gupta, V., Narayan, G., & Kumar, S. (2020). Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study. Journal of Cancer Research and Therapeutics, 16(1), 30-33.
Fiordi, B., Salvestrini, V., Gugliotta, G., Castagnetti, F., Curti, A., Speiser, D. E., ... & Trabanelli, S. (2023). IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia. Haematologica, 108(9), 2396.
Tahmasebi S, Alimohammadi M, Khorasani S, Rezaei N. Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in Cancer. In Handbook of Cancer and Immunology. 2022; pp. 1-25. Cham: Springer Int Publishing.
Al-abady, I., Kashmoola, M., & Al-khero, K. (2021). Clinico-Hematological Profile in patients with chronic myeloid leukemia. Annals of the College of Medicine Mosul, 43(1), 1-0.
Aslam, I., Ashraf, A., & Ergashboevna, A. Z. (2024). Demographic and Clinical Profile Of Chronic Myeloid Leukemia Patients in a Resource-Limited Setting: A Comprehensive Analysis. Research Focus, 3(5), 191-196.
Boersma, B., Jiskoot, W., Lowe, P., & Bourquin, C. (2021). The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy. Cytokine & growth factor reviews, 62, 1-14.
de Jonge, K. (2019). Characterisation of immune-modulating lymphocyte populations in melanoma patients (Doctoral dissertation, Université de Lausanne, Faculté de biologie et médecine).
Lissoni, P., Messina, G., Pelizzoni, F., Rovelli, F., Brivio, F., Monzon, A., ... & Di Fede, G. (2020). The fascination of cytokine immunological science. Journal of Infectiology and Epidemiology, 3(1).
Galland, S., Martin, P., Fregni, G., Letovanec, I., & Stamenkovic, I. (2020). Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins. Cancer letters, 484, 50-64.
Huynh-Russo, L. (2024). Improving Treatments for Peritoneal Metastasis Originating from Colorectal Cancer (Doctoral dissertation, University of Zurich).
Yuzhalin, A., & Kutikhin, A. (2014). Interleukins in cancer biology: their heterogeneous role. Academic Press.
Ahmood, A. A., Mohammed, M. J., & Taha, M. M. (2024). Alterations in Immune Parameters ADP, ANA, IL-1, IL-6, IL-8, STAT-4, and TNF Alpha in Patients with Rheumatoid Arthritis and Osteoarthritis. South Eastern European Journal of Public Health, 104–120. https://doi.org/10.70135/seejph.vi.1114
AL-Khateeb, S. M., Tahir, N. T., & Al-bayati, A. A. H. (2022). Immune and inflammatory cytokines profile in Iraqi patients with acute and chronic myeloid leukemia. Biomedicine, 42(2), 262-267.
Bütow, M., Testaquadra, F. J., Baumeister, J., Maié, T., Chatain, N., Jaquet, T., ... & Schemionek, M. (2022). Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition. Haematologica, 108(4), 1179.
Vitale, C., Boccellato, E., Comba, L., Jones, R., Perutelli, F., Griggio, V., & Coscia, M. (2021). Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia. Cancers, 13(15), 3856.
Brück, O., Dufva, O., Hohtari, H., Blom, S., Turkki, R., Ilander, M., ... & Mustjoki, S. (2020). Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood advances, 4(2), 274-286.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
